Cargando…

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected

OBJECTIVES: The emergence of new variants of concern (VOCs) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) around the world significantly complicated the exit from Coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to evaluate the serum neutralizing activity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gidari, Anna, Sabbatini, Samuele, Bastianelli, Sabrina, Pierucci, Sara, Busti, Chiara, Monari, Claudia, Luciani Pasqua, Barbara, Dragoni, Filippo, Schiaroli, Elisabetta, Zazzi, Maurizio, Francisci, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310664/ https://www.ncbi.nlm.nih.gov/pubmed/34320390 http://dx.doi.org/10.1016/j.jinf.2021.07.019

Ejemplares similares

Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2
por: Gidari, Anna, et al.
Publicado: (2022)

Nelfinavir: An Old Ally in the COVID-19 Fight?
por: Gidari, Anna, et al.
Publicado: (2022)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
por: Gidari, Anna, et al.
Publicado: (2022)

Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
por: Gidari, Anna, et al.
Publicado: (2023)

Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria
por: Schiaroli, Elisabetta, et al.
Publicado: (2022)

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm
por: Gidari, Anna, et al.
Publicado: (2020)

SARS-CoV-2 Survival on Surfaces and the Effect of UV-C Light
por: Gidari, Anna, et al.
Publicado: (2021)

Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
por: Fiaschi, Lia, et al.
Publicado: (2022)

Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies
por: Dragoni, Filippo, et al.
Publicado: (2022)

Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV
por: Papalini, Chiara, et al.
Publicado: (2020)

Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature
por: Gidari, Anna, et al.
Publicado: (2020)

The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication
por: Bianconi, Elisa, et al.
Publicado: (2023)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
por: Supasa, Piyada, et al.
Publicado: (2021)

SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione
por: Bartolini, Desirée, et al.
Publicado: (2021)

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients
por: Trombetta, Claudia Maria, et al.
Publicado: (2021)

BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level
por: Torti, Carlo, et al.
Publicado: (2021)

Sphingosine 1-Phosphate (S1P)/ S1P Receptor Signaling and Mechanotransduction: Implications for Intrinsic Tissue Repair/Regeneration
por: Sassoli, Chiara, et al.
Publicado: (2019)

The HIV Matrix Protein p17 Subverts Nuclear Receptors Expression and Induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes
por: Renga, Barbara, et al.
Publicado: (2012)

SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?
por: Meacci, Elisabetta, et al.
Publicado: (2020)

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
por: Collier, Dami A., et al.
Publicado: (2021)

Low Brachial Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19
por: Bianconi, Vanessa, et al.
Publicado: (2021)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents
por: Gurevich, Michael, et al.
Publicado: (2022)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
por: Paciaroni, Alessandro, et al.
Publicado: (2023)

HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes
por: Renga, Barbara, et al.
Publicado: (2012)

Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy
por: Di Giallonardo, Francesca, et al.
Publicado: (2021)

Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France
por: Di Domenico, Laura, et al.
Publicado: (2021)

Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
por: Li, Rong, et al.
Publicado: (2021)

Role of Nucleocapsid Protein Antigen Detection for Safe End of Isolation of SARS-CoV-2 Infected Patients with Long Persistence of Viral RNA in Respiratory Samples
por: Mencacci, Antonella, et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

The Interplay between Candida albicans, Vaginal Mucosa, Host Immunity and Resident Microbiota in Health and Disease: An Overview and Future Perspectives
por: Gaziano, Roberta, et al.
Publicado: (2023)

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections
por: Dupont, Liane, et al.
Publicado: (2021)

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants
por: Zani, Alberto, et al.
Publicado: (2021)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
por: Trinité, Benjamin, et al.
Publicado: (2021)

The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines
por: Yang, Xinyi, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
por: Graham, Carl, et al.
Publicado: (2021)

Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection
por: Vicenti, Ilaria, et al.
Publicado: (2022)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ohcs0bdhdo9betrgg4q15vfdoe